MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma

• DOI: 10.1016/j.isci.2024.109417
• Publication Date: 2024-03-04T16:41:53Z
• Authors: Lama Hasan Bou Issa; Léa Fléchon; William Laine; Aicha Ouelkdite; Silvia Gaggero; Adeline Cozzani; Remi Tilmont; Paul Chauvet; Nicolas Gower; Romanos Sklavenit...; Carine Brinster; Xavier Thuru; Yasmine Touil; Bruno Quesnel; Suman Mitra; Irene M. Ghobrial; Jérôme Kluza; Salomon Manier
• Keywords: Vulnerability

Multiple myeloma (MM) is an incurable hematological malignancy in which MYC alterations contribute to the malignant phenotype. Nevertheless, lacks therapeutic druggability. Here, we leveraged large-scale loss-of-function screens and conducted a small molecule screen identify genes pathways with enhanced essentiality correlated